4 transcripts
BMY
Earnings call transcript
NYSE
2024 Q2
26 Jul 24
to be impacted by competitive environment and the quality of commercial access in the U.S. At the same time, during Q2, we achieved improved commercial access
BMY
Earnings call transcript
NYSE
2024 Q1
25 Apr 24
patterns for Opdivo and Camzyos normalizing. And for SOTYKTU, we're steadily building commercial script volume as access continues to improve this year
BMY
Earnings call transcript
NYSE
2023 Q4
2 Feb 24
continues to be driving demand and broadening access. We made good progress on both fronts in the fourth quarter. Fourth quarter sales in the U.S. also
BMY
Earnings call transcript
NYSE
2023 Q2
27 Jul 23
of patients needing to access the free drug program.
So to sum up what this means financially, we estimate the impact of the increase in patients
- Prev
- 1
- Next